Comparative Pharmacology
Head-to-head clinical analysis: CORPHED versus DIPHENHYDRAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORPHED versus DIPHENHYDRAMINE.
CORPHED vs Diphenhydramine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corbined (idarucizumab) is a humanized monoclonal antibody fragment that binds to dabigatran with high affinity, neutralizing its anticoagulant effect. It acts as a specific reversal agent for dabigatran.
Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.
10-20 mg orally twice daily; maximum 60 mg/day.
25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).
None Documented
None Documented
Clinical Note
moderateDiphenhydramine + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Diphenhydramine."
Clinical Note
moderateDiphenhydramine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone propionate."
Clinical Note
moderateDiphenhydramine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Diphenhydramine."
Clinical Note
moderateTerminal half-life 3-4 hours; prolonged in renal impairment (up to 15 hours)
Terminal elimination half-life 4-8 hours in adults; prolonged in hepatic impairment (up to 20 hours) and elderly.
Renal (70-80% as unchanged drug), biliary/fecal (20-30%)
Primarily renal (90-95% as metabolites, <5% unchanged). Minor biliary/fecal elimination (<5%).
Category C
Category C
Antihistamine/Decongestant
Antihistamine
Diphenhydramine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Diphenhydramine."